Novocure Stock Forecast, Price & News

Novocure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVCR shares have increased by 58.7% and is now trading at $106.90.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novocure.

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Novocure.

Novocure Ltd (NASDAQ:NVCR) announced its earnings results on Thursday, July, 30th. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.01. The medical equipment provider had revenue of $115.90 million for the quarter, compared to the consensus estimate of $105.96 million. Novocure had a return on equity of 5.14% and a net margin of 2.88%. Novocure's revenue for the quarter was up 33.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.01) earnings per share.
View Novocure's earnings history.

10 analysts have issued 12-month price targets for Novocure's stock. Their forecasts range from $58.00 to $125.00. On average, they anticipate Novocure's stock price to reach $90.67 in the next twelve months. This suggests that the stock has a possible downside of 15.2%.
View analysts' price targets for Novocure.

Novocure saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 3,770,000 shares, an increase of 14.6% from the August 31st total of 3,290,000 shares. Based on an average daily volume of 1,110,000 shares, the days-to-cover ratio is currently 3.4 days. Currently, 4.5% of the company's stock are sold short.
View Novocure's Short Interest.

Some companies that are related to Novocure include Baxter International (BAX), DexCom (DXCM), FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Penumbra (PEN), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Hill-Rom (HRC), Globus Medical (GMED), Nevro (NVRO), Haemonetics (HAE) and Integra Lifesciences (IART).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), salesforce.com (CRM) and Roku (ROKU).

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Novocure's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (10.33%), Vanguard Group Inc. (7.39%), Macquarie Group Ltd. (0.93%), Two Sigma Advisers LP (0.88%), Mitsubishi UFJ Trust & Banking Corp (0.55%) and Rhenman & Partners Asset Management AB (0.37%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for Novocure.

NVCR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Macquarie Group Ltd., Nuveen Asset Management LLC, Charles Schwab Investment Management Inc., Frontier Capital Management Co. LLC, Healthcare of Ontario Pension Plan Trust Fund, Nicholas Investment Partners LP, and American International Group Inc.. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for Novocure.

NVCR stock was purchased by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Two Sigma Advisers LP, Cubist Systematic Strategies LLC, C WorldWide Group Holding A S, Canada Pension Plan Investment Board, Kornitzer Capital Management Inc. KS, New York State Common Retirement Fund, and State Board of Administration of Florida Retirement System.
View insider buying and selling activity for Novocure.

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCR stock can currently be purchased for approximately $106.90.

Novocure has a market capitalization of $10.81 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

The official website for Novocure is www.novocure.com.

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]